Mebufotenin benzoate- Beckley Psytech
Alternative Names: 5-MeO-DMT - Beckley Psytech; 5-Methoxy-N-N-Dimethyltryptamine - Beckley Psytech; BPL-002; BPL-003Latest Information Update: 26 Sep 2025
At a glance
- Originator Beckley Psytech
- Class Analgesics; Antidepressants; Behavioural disorder therapies; Ethers; Mood stabilisers; Small molecules; Tryptamines
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alcoholism; Major depressive disorder
Most Recent Events
- 23 Sep 2025 Efficacy and adverse events data from a phase IIa trial in Major depressive disorder released by atai Life Sciences
- 23 Sep 2025 atai Life Sciences plans a phase III trial for Major depressive disorders in the first half of 2026
- 14 Aug 2025 atai Life Sciences anticipates submission of end-of-phase 2 meeting request to the US FDA in the third quarter of 2025